Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK-3543) versus Hydroxyurea in Cytoreductive Therapy Naïve Essential Thrombocythemia Participants

Promotore
Merck Sharp & Dohme LLC (MSD)
Acronimo
MK3543-007
Struttura
Ematologia
Sperimentatore principale
Marchetti Monia
Stato arruolamento
In attesa di arruolamento
Unit di ricerca
Fase I